Skip to content
Clinical Trials – home
ItalyBack to Italy

Clinical trials in Bergamo – page 7

388 clinical trials in Bergamo, Italy across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Bergamo at a glance
388
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

388 trials in Bergamo

Open in trial search

Graves' disease

Recruiting

Study of IMVT-1402 Treatment for Adults with Graves' Disease

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Imeroprubart
  • Sponsor:Immunovant Sciences GmbH

Study of daratumumab, teclistamab and talquetamab combination treatment for frail patients with newly diagnosed multiple myeloma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:Emn Trial Office S.r.l. Impresa Sociale

Study of IMVT-1402 in Adults with Mild to Severe Generalized Myasthenia Gravis

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Imeroprubart
  • Sponsor:Immunovant Sciences GmbH

Study comparing GSK5764227 and topotecan in adults with relapsed small cell lung cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:GSK5764227
  • Sponsor:Glaxosmithkline Research & Development Limited

Study comparing remibrutinib and ocrelizumab in patients with relapsing multiple sclerosis who switch from ocrelizumab treatment

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Ocrelizumab
  • Sponsor:Novartis Pharma AG

Study of ziltivekimab compared to placebo in patients with acute heart attack to evaluate its effects on coronary artery plaque reduction

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Ziltivekimab
  • Sponsor:ECRI-trials B.V.

Study of sacituzumab tirumotecan, pembrolizumab and chemotherapy combination for early-stage triple-negative breast cancer or hormone receptor-low positive/HER2-negative breast cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Merck Sharp & Dohme LLC

Study of Patiromer to Allow Less Dietary Potassium Restrictions in Patients on Chronic Dialysis with Controlled Blood Potassium Levels

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Patiromer
  • Sponsor:Istituto Di Ricerche Farmacologiche Mario Negri

Study of AP31969 compared to placebo to control heart rhythm in patients with atrial fibrillation

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:AP31969 sulfate
  • Sponsor:Acesion Pharma ApS

Study of NX-5948 in adults with relapsed or resistant chronic lymphocytic leukemia and small lymphocytic lymphoma who previously received BTK inhibitor and BCL-2 inhibitor treatment

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:NX-5948
  • Sponsor:Nurix Therapeutics Inc.

Study of patritumab deruxtecan versus drug combination in patients with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Merck Sharp & Dohme LLC

Study of gilteritinib with fludarabine, cytarabine and idarubicin combination therapy in newly diagnosed FLT3-positive acute myeloid leukemia patients

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Gilteritinib
  • Sponsor:Fondazione Gimema Franco Mandelli Onlus

Other cities in Italy

The busiest research cities in the country

All 237 cities in Italy

Clinical research in Bergamo

What the registry says about research in the country

01 Cardiovascular Research

Innovative trials exploring treatments for heart failure prevention and cardiovascular disease. Studies include evaluation of novel drug combinations and therapies for patients with elevated cardiovascular risks.

  • Heart Failure Prevention
  • Myocardial Infarction Treatment
  • Cardiovascular Risk Management
02 Oncology Studies

Comprehensive research focusing on various cancer types, including non-small cell lung cancer and prostate cancer. Studies evaluate innovative treatment approaches combining immunotherapy with traditional methods.

  • Lung Cancer Therapies
  • Prostate Cancer Treatment
  • Breast Cancer Research
03 Rare Diseases

Specialized trials investigating treatments for conditions like Alagille syndrome and amyotrophic lateral sclerosis. Research focuses on improving patient outcomes and quality of life.

  • Genetic Disorders
  • Neurological Conditions
  • Rare Blood Disorders
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.